Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic pulmonary embolism with or without symptomatic deep vein thrombosis~Exclusion Criteria:~* End stage renal failure, hepatic failure, uncontrolled hypertension;~* Active bleeding or high risk for bleeding;~* Pregnancy or childbearing potential without proper contraceptive measures, threatened abortion.~* Breastfeeding.~* Known allergy to idraparinux or idrabiotaparinux, avidin or egg proteins;~* hypersensitivity to warfarin, enoxaparin, heparin or pork product; or any other contraindication listed in the labelling of warfarin or enoxaparin;~* Indication of prolonged anticoagulation therapy for other reason than PE;~* Life expectancy \< 6 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idrabiotaparinux (Type: EXPERIMENTAL): Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage).
- Warfarin (Type: ACTIVE_COMPARATOR): Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage).

Based on this trial design, predict the completion outcome and termination type (if applicable).